SERI and Carl Zeiss Meditec partner to advance ophthalmic surgery

The partnership will support different research projects over the next three years.

The Singapore Eye Research Institute (SERI) and Carl Zeiss Meditec AG have entered into a strategic partnership to enhance surgical outcomes in refractive and cataract surgeries.

The collaboration, titled “OPhthalmic Tech Innovation by ZEISS and SERI (OPTIZS)”, is supported by nearly $15m (S$20m) in funding under Singapore's “Research, Innovation and Enterprise 2025 Plan”.

The partnership will support different research projects over the next three years focused on improving clinical outcomes and innovation.

ZEISS and SERI will also work to develop more personalised solutions and improve surgical processes for faster visual rehabilitation and better long-term stability.

Both parties will also explore providing new treatments for presbyopia and improving outcomes for patients with myopia.

S$1 = $0.74